<DOC>
<DOCNO>
EP-0002495
</DOCNO>
<TEXT>
<DATE>
19790627
</DATE>
<IPC-CLASSIFICATIONS>
A61K-31/185 A61K-31/675 A61P-39/02 A61P-39/00 <main>A61K-31/66</main> A61P-35/00 
</IPC-CLASSIFICATIONS>
<TITLE>
composition for use in cytostatic therapy.
</TITLE>
<APPLICANT>
asta werke ag chem fabde  <sep>asta-werke aktiengesellschaft chemische fabrik<sep>asta-werke aktiengesellschaft chemische fabrikartur-ladebeck-strasse 128 - 152 postfach 14 01 29d-4800 bielefeld 14de<sep>asta-werke aktiengesellschaft chemische fabrik  <sep>
</APPLICANT>
<INVENTOR>
brock norbert prof dr<sep>brock, norbert, prof. dr.<sep>brock, norbert, prof. dr.am rehhagen 10d-4800 bielefeld 1de<sep>brock, norbert, prof. dr.<sep>brock, norbert, prof. dr.am rehhagen 10d-4800 bielefeld 1de<sep>
</INVENTOR>
<ABSTRACT>
The invention relates to the novel use of pharmacologically acceptable salts of mercaptoalkanesulfonic acids of the general formula HS-Al-Al-SO‚ÇÉH in the cytostatic therapy with alkylants with the surprising result, that the strong irritation caused by alkylants, urinary tracts and bubble, often a termination of theCytostatic therapy necessary, no longer occur.
</ABSTRACT>
</TEXT>
</DOC>
